What is Fyremadel ?

Ganirelix Acetate is a synthetic decapeptide that acts as a gonadotropin-releasing hormone (GnRH) antagonist. By competitively binding to GnRH receptors in the pituitary gland, it effectively inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), preventing premature ovulation in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies. This targeted approach helps optimize the timing of oocyte retrieval and enhances the chances of successful fertilization and pregnancy.

• Nausea
• Headache
• Abdominal pain
• Injection site reactions (e.g., redness, swelling, or pain)
• Vaginal bleeding
• Dizziness

• Hypersensitivity reactions: Patients with known hypersensitivity to Ganirelix Acetate or any component of the product should avoid use.
• Ovarian hyperstimulation syndrome (OHSS): May occur in some cases and requires immediate medical attention.
• Ectopic pregnancy: Monitor patients closely, as there may be a risk after treatment.
• Thromboembolic events: Use with caution in patients with a history of or predisposition to thromboembolic disorders.
• Lung and breathing issues: Caution is advised, as respiratory distress or lung issues may occur.
• Injection site inflammation: Monitor for severe reactions at the site of injection.